文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

胸苷激酶1驱动皮肤黑色素瘤的恶性进展和代谢重编程。

Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming.

作者信息

Zuo Sipeng, Wang Huixue, Li Lin, Pan Hui, Lu Linna

机构信息

Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.

出版信息

Front Oncol. 2022 Mar 3;12:802807. doi: 10.3389/fonc.2022.802807. eCollection 2022.

DOI:10.3389/fonc.2022.802807
PMID:35311151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8927676/
Abstract

BACKGROUND: Thymidine kinase 1 (TK1) is a cell cycle-dependent kinase that catalyzes the addition of a gamma-phosphate group to thymidine. The protumorigenic role of TK1 has been reported in various malignancies. However, the role of TK1 in skin cutaneous melanoma (SKCM) remains unclear. This study aimed to explore the molecular function of TK1 in SKCM progression. METHODS: Bioinformatics data were acquired from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Subcutaneous xenografts were established to observe the effect of TK1 knockdown on the proliferation of SKCM cells . RNA sequencing (RNA-seq; deposited in Sequence Read Archive, SRX10950283-SRX10950285 for A375 control cells and SRX10950286-SRX10950288 for TK1-silenced A375 cells) and immunoprecipitation-mass spectrometry (IP-MS) were used to analyze TK1-related genes and pathways. Seahorse XF Cell Mito tests and glycolysis stress assays were conducted for metabolic testing. RESULTS: TK1 was upregulated in malignant SKCM compared to that in normal tissues and cell lines. Elevated expression of TK1 was associated with poor prognosis. and assays demonstrated that TK1 promoted the proliferation and migration of SKCM cells. Moreover, TK1 was strongly associated with multiple intracellular metabolic pathways, facilitating cell mitochondrial respiration and glycolysis in SKCM malignant progression. CONCLUSIONS: TK1 drives SKCM malignant progression and supports metabolic reprogramming, indicating that TK1 serves as a therapeutic target for SKCM.

摘要

背景：胸苷激酶1（TK1）是一种细胞周期依赖性激酶，可催化将γ-磷酸基团添加到胸苷上。TK1在各种恶性肿瘤中的促肿瘤作用已有报道。然而，TK1在皮肤黑色素瘤（SKCM）中的作用仍不清楚。本研究旨在探讨TK1在SKCM进展中的分子功能。 方法：从癌症基因组图谱（TCGA）和基因表达综合数据库（GEO）获取生物信息学数据。建立皮下异种移植模型以观察TK1敲低对SKCM细胞增殖的影响。采用RNA测序（RNA-seq；A375对照细胞的数据存于序列读取存档库，编号为SRX10950283 - SRX10950285，TK1沉默的A375细胞的数据存于序列读取存档库，编号为SRX10950286 - SRX10950288）和免疫沉淀-质谱分析（IP-MS）来分析与TK1相关的基因和信号通路。进行海马XF细胞线粒体检测和糖酵解应激试验以进行代谢测试。 结果：与正常组织和细胞系相比，恶性SKCM中TK1表达上调。TK1表达升高与预后不良相关。 试验和 试验表明，TK1促进SKCM细胞的增殖和迁移。此外，TK1与多种细胞内代谢途径密切相关，在SKCM恶性进展过程中促进细胞线粒体呼吸和糖酵解。 结论：TK1驱动SKCM恶性进展并支持代谢重编程，表明TK1可作为SKCM的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/d196085ee108/fonc-12-802807-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/c8d938abcdc0/fonc-12-802807-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/653eda7dc3a1/fonc-12-802807-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/4240119d7946/fonc-12-802807-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/d99a63d083c2/fonc-12-802807-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/f17f6444c670/fonc-12-802807-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/3f0e49f5e96b/fonc-12-802807-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/e38a164b0032/fonc-12-802807-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/d196085ee108/fonc-12-802807-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/c8d938abcdc0/fonc-12-802807-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/653eda7dc3a1/fonc-12-802807-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/4240119d7946/fonc-12-802807-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/d99a63d083c2/fonc-12-802807-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/f17f6444c670/fonc-12-802807-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/3f0e49f5e96b/fonc-12-802807-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/e38a164b0032/fonc-12-802807-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf7/8927676/d196085ee108/fonc-12-802807-g008.jpg

相似文献

[1]
Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming.

Front Oncol. 2022-3-3

[2]
FANCI serve as a prognostic biomarker correlated with immune infiltrates in skin cutaneous melanoma.

Front Immunol. 2023

[3]
LSM2 is associated with a poor prognosis and promotes cell proliferation, migration, and invasion in skin cutaneous melanoma.

BMC Med Genomics. 2023-6-13

[4]
promotes melanoma progression through rewiring cell glucose metabolism.

Ann Transl Med. 2022-1

[5]
Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients.

Cancer Cell Int. 2020-5-25

[6]
HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma.

Cancer Cell Int. 2023-6-21

[7]
PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma.

Cell Death Discov. 2021-10-29

[8]
High Expression of TIMELESS Predicts Poor Prognosis: A Potential Therapeutic Target for Skin Cutaneous Melanoma.

Front Surg. 2022-5-19

[9]
α-Enolase inhibits apoptosis and promotes cell invasion and proliferation of skin cutaneous melanoma.

Mol Biol Rep. 2022-9

[10]
GBP2 Is a Favorable Prognostic Marker of Skin Cutaneous Melanoma and Affects Its Progression via the Wnt/β-catenin Pathway.

Ann Clin Lab Sci. 2021-11

引用本文的文献

[1]
Identification of pyrimidine metabolism-based molecular subtypes and prognostic signature to predict immune landscape and guide clinical treatment in prostate cancer.

Ann Med. 2025-12

[2]
A comprehensive analysis and experimental validation of TK1 in uterine corpus endometrial carcinoma.

Sci Rep. 2024-3-13

[3]
Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.

Front Immunol. 2023

[4]
Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy.

Cancer Res Commun. 2023-5

[5]
Multi-Omics Integration Analysis of TK1 in Glioma: A Potential Biomarker for Predictive, Preventive, and Personalized Medical Approaches.

Brain Sci. 2023-1-30

本文引用的文献

[1]
Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF/NRAS Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model.

J Invest Dermatol. 2022-5

[2]
Immune checkpoint inhibitors in melanoma.

Lancet. 2021-9-11

[3]
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.

Cancer Cell. 2021-10-11

[4]
Cancer metabolism: looking forward.

Nat Rev Cancer. 2021-10

[5]
Recent Advances in the Treatment of Melanoma.

N Engl J Med. 2021-6-10

[6]
Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma.

Cancer Res. 2021-7-15

[7]
Advances in Targeting Cutaneous Melanoma.

Cancers (Basel). 2021-4-26

[8]
CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism.

Cell Chem Biol. 2021-10-21

[9]
Novel adjuvant options for cutaneous melanoma.

Ann Oncol. 2021-7

[10]
Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence.

Cancer Lett. 2021-6-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索